BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DO-2 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DO-2\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05752552-2457@assetmemo.bio
DTSTAMP:20261121T004335Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:DO-2: Phase 1 readout est. (NCT05752552)
DESCRIPTION:DO-2\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study to D
 etermine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced
  or Refractory Solid Tumours\nEstimated primary completion: September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/do-2#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05752552
URL:https://assetmemo.bio/drug/do-2#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
